Device type · MDS
Sensor, Glucose, Invasive
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
MDS
Clinical Chemistry
Device class
Class III
FDA decisions since 2015
6
510(k), De Novo and PMA
Adverse event reports
2,843
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Sensor, Glucose, Invasive
- Product code
- MDS
- Device class
- Class III
- Review panel
- Clinical Chemistry
- FDA record
- Classification database entry for MDS
Latest FDA decisions
P160007 · Decided Mar 8, 2018 · 730 days after receipt
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
P150021 · Decided Sep 23, 2016 · 462 days after receipt
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
P150029 · Decided Jun 17, 2016 · 312 days after receipt
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
- ANIMAS VIBE SYSTEMPMA supplement
P130007-S004 · Decided Dec 24, 2015 · 238 days after receipt · Panel Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
P150019 · Decided Dec 7, 2015 · 180 days after receipt
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
P120005-S031 · Decided May 22, 2015 · 177 days after receipt · Panel Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
Reports received
2,843
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
2,732
96% of reports
Injury reports
110
3.9% of reports
Death reports
1
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 338 | 4 | 0 | 0 |
| Jan 24 | 815 | 1 | 0 | 0 |
| Feb 24 | 435 | 4 | 0 | 0 |
| Mar 24 | 372 | 1 | 0 | 0 |
| Apr 24 | 339 | 11 | 0 | 0 |
| May 24 | 532 | 5 | 0 | 0 |
| Jun 24 | 270 | 2 | 0 | 0 |
| Jul 24 | 354 | 4 | 0 | 0 |
| Aug 24 | 220 | 3 | 0 | 0 |
| Sep 24 | 223 | 1 | 0 | 0 |
| Oct 24 | 193 | 0 | 0 | 0 |
| Nov 24 | 126 | 2 | 0 | 0 |
| Dec 24 | 224 | 1 | 0 | 0 |
| Jan 25 | 168 | 5 | 0 | 2 |
| Feb 25 | 125 | 4 | 0 | 0 |
| Mar 25 | 131 | 4 | 0 | 0 |
| Apr 25 | 194 | 1 | 0 | 0 |
| May 25 | 215 | 3 | 1 | 0 |
| Jun 25 | 180 | 5 | 0 | 0 |
| Jul 25 | 221 | 12 | 0 | 0 |
| Aug 25 | 205 | 15 | 0 | 0 |
| Sep 25 | 275 | 17 | 0 | 0 |
| Oct 25 | 163 | 15 | 0 | 0 |
| Nov 25 | 620 | 13 | 0 | 0 |
| Dec 25 | 228 | 13 | 0 | 0 |
| Jan 26 | 172 | 17 | 1 | 0 |
| Feb 26 | 214 | 6 | 0 | 0 |
| Mar 26 | 295 | 8 | 0 | 0 |
| Apr 26 | 241 | 11 | 0 | 0 |
| May 26 | 177 | 13 | 0 | 0 |
| Jun 26 | 139 | 6 | 0 | 0 |
| Jul 26 | 188 | 3 | 0 | 0 |
| Aug 26 | 148 | 9 | 0 | 0 |
| Sep 26 | 159 | 4 | 0 | 0 |
| Oct 26 | 151 | 7 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
- Medtronic2,832
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Wireless Communication Problem2,205
- Incorrect, Inadequate or Imprecise Result or Readings257
- Data Problem247
- Battery Problem86
- Calibration Problem69
- Computer Software Problem69
- Display or Visual Feedback Problem28
- Device Alarm System27
- Unauthorized Access to Computer System10
- Break7
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions2,493
- Hyperglycemia170
- Hypoglycemia115
- Hemorrhage/Blood Loss/Bleeding57
- Elevated Ketones/ Diabetic Ketoacidosis15
- Malaise9
- Bruise/Contusion8
- Device Embedded In Tissue or Plaque7
- Vomiting7
- Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available6
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Medtronic, Simplera Sensor, REF: MMT-5100JD1Open, Classified
Z-0033-2026 · Started May 7, 2025 · Posted by FDA Oct 2, 2025
Reason given: The device cap label may not adhere to the sensor, compromising the sterility of the sensor, and increasing the risk of infection.
Cause as FDA categorized it: Process design
- Guardian iOS app (MMT-8200) and Guardian Android app (MMT-8201), part of the Guardian 4 systemOpen, Classified
Z-0776-2023 · Started Nov 21, 2022 · Posted by FDA Jan 1, 2023
Reason given: An app, part of a continuous glucose monitoring system, for use with smartphone devices may automatically log out from CareLink, then the app is not able to upload data. When logged out, linked care partners will not receive SMS notifications (could result in hypoglycemia or hyperglycemia), and sensor glucose values...
Cause as FDA categorized it: Software change control
Z-1599-2021 · Started Feb 26, 2021
Reason given: Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose readings.
Cause as FDA categorized it: Under Investigation by firm
Z-1600-2021 · Started Feb 26, 2021
Reason given: Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose readings.
Cause as FDA categorized it: Under Investigation by firm
Z-1601-2021 · Started Feb 26, 2021
Reason given: Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose readings.
Cause as FDA categorized it: Under Investigation by firm
Z-1602-2021 · Started Feb 26, 2021
Reason given: Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose readings.
Cause as FDA categorized it: Under Investigation by firm
Z-1603-2021 · Started Feb 26, 2021
Reason given: Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose readings.
Cause as FDA categorized it: Under Investigation by firm
Z-1604-2021 · Started Feb 26, 2021
Reason given: Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose readings.
Cause as FDA categorized it: Under Investigation by firm
Showing the 8 newest of 57 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.